These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
190 related articles for article (PubMed ID: 34853152)
81. Differential manipulation of arrestin-3 binding to basal and agonist-activated G protein-coupled receptors. Prokop S; Perry NA; Vishnivetskiy SA; Toth AD; Inoue A; Milligan G; Iverson TM; Hunyady L; Gurevich VV Cell Signal; 2017 Aug; 36():98-107. PubMed ID: 28461104 [TBL] [Abstract][Full Text] [Related]
82. Structural Insights into β-arrestin/CB1 Receptor Interaction: NMR and CD Studies on Model Peptides. Morales P; Bruix M; Jiménez MA Int J Mol Sci; 2020 Oct; 21(21):. PubMed ID: 33143110 [TBL] [Abstract][Full Text] [Related]
83. Bioluminescence Resonance Energy Transfer (BRET) to Detect the Interactions Between Kappa Opioid Receptor and Nonvisual Arrestins. Bedini A Methods Mol Biol; 2021; 2201():45-58. PubMed ID: 32975788 [TBL] [Abstract][Full Text] [Related]
84. Noncanonical interactions of G proteins and β-arrestins: from competitors to companions. Smith JS; Pack TF FEBS J; 2021 Apr; 288(8):2550-2561. PubMed ID: 33539669 [TBL] [Abstract][Full Text] [Related]
85. G-protein-coupled receptor kinase specificity for beta-arrestin recruitment to the beta2-adrenergic receptor revealed by fluorescence resonance energy transfer. Violin JD; Ren XR; Lefkowitz RJ J Biol Chem; 2006 Jul; 281(29):20577-88. PubMed ID: 16687412 [TBL] [Abstract][Full Text] [Related]
86. Kinetics of CXCL12 binding to atypical chemokine receptor 3 reveal a role for the receptor N terminus in chemokine binding. Gustavsson M; Dyer DP; Zhao C; Handel TM Sci Signal; 2019 Sep; 12(598):. PubMed ID: 31506383 [TBL] [Abstract][Full Text] [Related]
88. Cell-based high-throughput screening assay system for monitoring G protein-coupled receptor activation using beta-galactosidase enzyme complementation technology. Yan YX; Boldt-Houle DM; Tillotson BP; Gee MA; D'Eon BJ; Chang XJ; Olesen CE; Palmer MA J Biomol Screen; 2002 Oct; 7(5):451-9. PubMed ID: 14599361 [TBL] [Abstract][Full Text] [Related]
89. Functional characterization of β Susec M; Sencanski M; Glisic S; Veljkovic N; Pedersen C; Drinovec L; Stojan J; Nøhr J; Vrecl M Neuropharmacology; 2019 Jul; 152():78-89. PubMed ID: 30707913 [TBL] [Abstract][Full Text] [Related]
90. New Insights into Arrestin Recruitment to GPCRs. Spillmann M; Thurner L; Romantini N; Zimmermann M; Meger B; Behe M; Waldhoer M; Schertler GFX; Berger P Int J Mol Sci; 2020 Jul; 21(14):. PubMed ID: 32668755 [TBL] [Abstract][Full Text] [Related]
96. Molecular determinants of ligand efficacy and potency in GPCR signaling. Heydenreich FM; Marti-Solano M; Sandhu M; Kobilka BK; Bouvier M; Babu MM Science; 2023 Dec; 382(6677):eadh1859. PubMed ID: 38127743 [TBL] [Abstract][Full Text] [Related]
97. Lipids and Phosphorylation Conjointly Modulate Complex Formation of β Pluhackova K; Wilhelm FM; Müller DJ Front Cell Dev Biol; 2021; 9():807913. PubMed ID: 35004696 [TBL] [Abstract][Full Text] [Related]
98. Resistance of the human beta 1-adrenergic receptor to agonist-mediated down-regulation. Role of the C terminus in determining beta-subtype degradation. Liang W; Austin S; Hoang Q; Fishman PH J Biol Chem; 2003 Oct; 278(41):39773-81. PubMed ID: 12888573 [TBL] [Abstract][Full Text] [Related]
99. Biased signaling in naturally occurring mutations of G protein-coupled receptors associated with diverse human diseases. Yang LK; Hou ZS; Tao YX Biochim Biophys Acta Mol Basis Dis; 2021 Jan; 1867(1):165973. PubMed ID: 32949766 [TBL] [Abstract][Full Text] [Related]
100. Structure and dynamics of GPCR signaling complexes. Hilger D; Masureel M; Kobilka BK Nat Struct Mol Biol; 2018 Jan; 25(1):4-12. PubMed ID: 29323277 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]